The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Boehringer Ingelheim (Inst); PharmaMar (Inst); Roche (Inst); Sanofi (Inst)
FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer.
 
Candice Carola
No Relationships to Disclose
 
Francois Ghiringhelli
No Relationships to Disclose
 
Stefano Kim
No Relationships to Disclose
 
Thierry Andre
Honoraria - Baxter; BAYER; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD Oncology; Novartis; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche/Genentech
 
Juliette Barlet
No Relationships to Disclose
 
Leila Bengrine
No Relationships to Disclose
 
Helene Marijon
No Relationships to Disclose
 
Marie Line Garcia
No Relationships to Disclose
 
Christophe Borg
No Relationships to Disclose
 
Linda Dainese
No Relationships to Disclose
 
Nils Steuer
No Relationships to Disclose
 
Annette K Larsen
No Relationships to Disclose
 
Aimery De Gramont
Honoraria - Chugai Pharma; Yakult Pharmaceutical
 
Benoist Chibaudel
No Relationships to Disclose